The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.

ABSTRACT:

Background

B cell maturation antigen (BCMA) targeted immunotherapies have demonstrated remarkable clinical efficacy in multiple myeloma (MM). Here, we evaluated the BCMA expression in MM and other plasma cell dyscrasias (PCDs), hoping to provide a potential treatment strategy for the relapsed/refractory PCDs besides MM.

Methods

From January 2018 to August 2021, 377 patients with PCDs were enrolled in this study, including 334 MM, 21 systemic light chain amyloidosis (AL), 5 POEMS syndrome, 14 monoclonal gammopathy of undetermined significance (MGUS), and three monoclonal gammopathy of renal significance (MGRS). The membrane-bound BCMA expression measured by multiparameter flow cytometry was defined by BCMA positivity rate and the mean fluorescence intensity (MFI).

Results<

SUBMITTER: Xu Y 

PROVIDER: S-EPMC9903528 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature